Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $45.42 (market cap $2.51B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bear 3X Shares for 11 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SOXS | TVTX | |
|---|---|---|
Market Cap | $2.51B | $5.02B |
Volume | 88,764,629 | 2,060,842 |
Sector | Leveraged / Inverse | Health |
52-Week High | $944.00 | $67.52 |
52-Week Low | $29.62 | $26.79 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS trades at $37.42, up 0.48% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The ETF faces significant volatility as a 3x leveraged inverse semiconductor fund, with recent performance driven by semiconductor sector weakness. Recent news highlights ongoing challenges in the semiconductor space, including Nvidia's China exposure and competitive pressures.
As a tactical inverse ETF, SOXS offers short-term hedging potential against semiconductor declines but carries substantial decay risks for long-term holders. The fund's structure makes it unsuitable for buy-and-hold strategies, with success dependent on accurately timing semiconductor sector downturns amid persistent AI demand.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
